StackTerminal.Health

BETA
Research compound

This compound is primarily studied in research/clinical settings & may not be widely available as a regulated over-the-counter supplement. Information is provided for educational purposes only — not as a recommendation to use. See our Safety page.

Tirzepatide

Tirzepatide is a dual GIP/GLP-1 receptor co-agonist approved for the treatment of type 2 diabetes and obesity, demonstrating significant weight loss and metabolic control in clinical trials.

weight-lossmetabolicblood-sugarappetite
Evidence last reviewed: 19 Apr 2026
Buy this ingredient← Back
Supplement note
Private note on this supplement

Save how you reacted, what dose worked, what to watch for, or anything you want to remember later in your Notes tab.

Sign in to keep a private note on Tirzepatide.
Sign in
Biomarkers studied
Outcomes directly measured across the evidence records below
Sleep
Sleep Quality (subjective)
Cardiovascular
Blood PressureLDL Cholesterol
Metabolic
Body WeightBody Fat %Blood GlucoseHbA1c
Bloodwork
ALT / AST (Liver)
Evidence
5 records
Obstructive sleep apnea improvement
Adults with obesity and obstructive sleep apnea • RCT
PUBMEDModerate

Tirzepatide significantly reduced the apnea-hypopnea index compared to placebo.

Dose: 15 mgDuration: 52 weeksForm: Subcutaneous injectionTiming: Once weekly
Citation: Forzano et al. (2022). Tirzepatide: A Systematic Update. EClinicalMedicine.
Improvement in sleep-related outcomes.
Liver health
Adults with metabolic dysfunction-associated steatohepatitis • RCT
PUBMEDModerate

Tirzepatide showed potential in improving liver fibrosis and reducing liver fat.

Dose: 15 mgDuration: 52 weeksForm: Subcutaneous injectionTiming: Once weekly
Citation: Loomba et al. (2024). Tirzepatide for Metabolic Dysfunction-Associated Steatohepatitis with Liver Fibrosis. Nature Medicine.
Weight reduction
Adults with obesity • RCT
PUBMEDHigh

Tirzepatide led to a mean weight reduction of 25.3% compared to 9.9% with placebo.

Dose: 15 mgDuration: 88 weeksForm: Subcutaneous injectionTiming: Once weekly
Citation: Nicholls et al. (2024). Comparison of tirzepatide and dulaglutide on major adverse cardiovascular events in participants with type 2 diabetes and atherosclerotic cardiovascular disease: SURPASS-CVOT design and baseline characteristics. JAMA.
Significant weight loss maintained over 88 weeks.
Glycemic control
Adults with type 2 diabetes • Systematic review
PUBMEDHigh

Tirzepatide improved glycemic control compared to other GLP-1 receptor agonists.

Dose: 15 mgDuration: 36 weeksForm: Subcutaneous injectionTiming: Once weekly
Citation: Yao et al. (2024). Comparative effectiveness of GLP-1 receptor agonists on glycaemic control, body weight, and lipid profile for type 2 diabetes: systematic review and network meta-analysis. CMAJ.
Cardiovascular risk reduction
Adults with type 2 diabetes and cardiovascular disease • RCT
PUBMEDHigh

Tirzepatide reduced major adverse cardiovascular events compared to placebo.

Dose: 15 mgDuration: 88 weeksForm: Subcutaneous injectionTiming: Once weekly
Citation: Nicholls et al. (2024). Comparison of tirzepatide and dulaglutide on major adverse cardiovascular events in participants with type 2 diabetes and atherosclerotic cardiovascular disease: SURPASS-CVOT design and baseline characteristics. JAMA.
Forms
Subcutaneous injection
Administered once weekly.

Stacks containing Tirzepatide

Public community stacks that include this ingredient.

Explore all stacks →
No public stacks include this ingredient yet.